Study summary · research use only
Oral GLP-1 Receptor Agonists for Weight Loss
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review discusses oral GLP-1 receptor agonists for weight loss, focusing on semaglutide, danuglipron, and orforglipron. It notes that oral semaglutide was approved by the Food and Drug Administration for type 2 diabetes in 2019, and that injectable obesity medications are currently the most potent options available, prompting interest in developing comparable oral drugs. The review states that oral semaglutide is FDA-approved but not specifically for obesity, and examines future directions for these agents related to weight loss and cardiovascular disease in patients with obesity and overweight.
Abstract
With the increasing prevalence of obesity and the advent of new and highly effective antiobesity medications, there is renewed interest in novel antiobesity pharmacotherapy. Currently, the most effective medications for obesity are injectable medicines. There is a need to develop equally efficacious oral drugs to increase availability to patients. Oral semaglutide was approved by the Food and Drug Administration for type 2 diabetes in 2019. Herein, we review the current literature regarding the use of oral GLP-1 receptor agonists specifically for obesity including semaglutide, danuglipron, and orforglipron, with a focus on oral semaglutide as it is Food and Drug Administration-approved, although not for obesity alone. We also examine the future directions and impacts it will have on patients with obesity and overweight related to weight loss and cardiovascular disease.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.